- Home
- SXTC vs WINT Comparison
SXTC vs WINT Comparison
Compare SXTC & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTC
- WINT
- Stock Information
- Founded
- SXTC 2005
- WINT 1992
- Country
- SXTC China
- WINT United States
- Employees
- SXTC N/A
- WINT N/A
- Industry
- SXTC Biotechnology: Pharmaceutical Preparations
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SXTC Health Care
- WINT Health Care
- Exchange
- SXTC Nasdaq
- WINT Nasdaq
- Market Cap
- SXTC N/A
- WINT 1.5M
- IPO Year
- SXTC 2019
- WINT 1995
- Fundamental
- Price
- SXTC $2.57
- WINT $1.20
- Analyst Decision
- SXTC
- WINT Hold
- Analyst Count
- SXTC 0
- WINT 1
- Target Price
- SXTC N/A
- WINT $350.00
- AVG Volume (30 Days)
- SXTC 1.6M
- WINT 7.7M
- Earning Date
- SXTC 01-01-0001
- WINT 04-15-2025
- Dividend Yield
- SXTC N/A
- WINT N/A
- EPS Growth
- SXTC N/A
- WINT N/A
- EPS
- SXTC N/A
- WINT N/A
- Revenue
- SXTC $1,928,497.00
- WINT N/A
- Revenue This Year
- SXTC N/A
- WINT N/A
- Revenue Next Year
- SXTC N/A
- WINT N/A
- P/E Ratio
- SXTC N/A
- WINT N/A
- Revenue Growth
- SXTC N/A
- WINT N/A
- 52 Week Low
- SXTC $2.40
- WINT $1.10
- 52 Week High
- SXTC $26.96
- WINT $737.50
- Technical
- Relative Strength Index (RSI)
- SXTC 46.45
- WINT 27.23
- Support Level
- SXTC $2.66
- WINT $1.22
- Resistance Level
- SXTC $3.09
- WINT $2.17
- Average True Range (ATR)
- SXTC 0.22
- WINT 0.32
- MACD
- SXTC -0.15
- WINT 0.20
- Stochastic Oscillator
- SXTC 0.00
- WINT 3.54
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.